3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1
1
Status
Active not recruiting
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Lymphoid
2
Sarcoma
1
Plasma cell
1
Other hematologic neoplasm
1
Genitourinary
1
CNS
1
Conditions
Lymphoma, Non-Hodgkin
2
Lymphoma
2
Glioma
2
Wilms Tumor
1
Waldenstrom Macroglobulinemia
1
Triple Negative Breast Neoplasms
1
Sarcoma, Synovial
1
Sarcoma, Ewing
1
Sarcoma
1
Rhabdomyosarcoma
1
Rhabdoid Tumor
1
Recurrence
1
Paraproteinemias
1
Osteosarcoma
1
Neuroectodermal Tumors, Primitive
1
Neuroblastoma
1
Neoplasms, Plasma Cell
1
Neoplasms, Neuroepithelial
1
Neoplasms
1
Multiple Myeloma
1
Medulloblastoma
1
Lymphoproliferative Disorders
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, B-Cell, Marginal Zone
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Immunoproliferative Disorders
1
Hodgkin Disease
1
Hematologic Diseases
1
Head and Neck Neoplasms
1
Interventions
Cyclophosphamide
61
Rituximab
50
fludarabine
34
Prednisone
33
Doxorubicin
28
Biopsy
26
Vincristine
25
Specimen Handling
22
Magnetic Resonance Spectroscopy
20
Bendamustine Hydrochloride
19
pembrolizumab
16
Lenalidomide
16
obinutuzumab
14
fludarabine phosphate
14
Etoposide
14
venetoclax
13
Tacrolimus
11
Mycophenolic Acid
10
Melphalan
10
Dexamethasone
10
zanubrutinib
9
ibrutinib
9
acalabrutinib
9
Radiotherapy
9
Gemcitabine
9
Cytarabine
9
Busulfan
9
Whole-Body Irradiation
8
Mesna
8
Filgrastim
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Lymphoma
×
CLR1404
×
1 year
×
Clear all
NCT02952508
2026-03-18
CLOVER-WaM
Cellectar Biosciences, Inc.
Phase 2
Active not recruiting
120 enrolled
NCT03478462
2026-03-18
CLOVER-2
Cellectar Biosciences, Inc.
Phase 1
Active not recruiting
30 enrolled